Abstract:Introduction: Ineffective treatments and late detection combine to give pancreatic cancer (PC) patients especially poor prognosis. However, as more targeted therapies are approved and are being investigated, there is hope for such therapies to play a pivotal role in improving PC patient outcomes. KRAS is an important oncogenic driver in most pancreatic cancers, making the RAS signaling pathway an obvious therapy target. In this study we examine the genomic profile of pancreatic cancers that do or do not harbor a RAS alteration to identify other oncogenic drivers that may represent therapy targets. Methods: Pancreatic tumor samples were profiled using the OncoExTraTM tumor-normal, whole exome, whole transcriptome sequencing assay. This assay detects somatic single base substitutions, indels, copy number alterations, gene fusions and alternative transcripts. Actionable altered genes, defined as those with associated FDA-approved targeted therapies in any cancer type, those in guidelines or with published evidence for matched therapies, or those required for eligibility for an active clinical trial, were identified. Results: A total of 384 pancreatic patients were profiled, 305 (79.4%) of which harbored 310 KRAS alterations. Most KRAS alterations were missense mutations (307 of 310; 99.0%). Most (283) missenses caused a substitution at amino acid position 12, with G12D (n=115), G12V (n=104) and G12R (n=54) being the most common. There were also 3 missense substitutions at position 13, and 21 at position 61. In addition, three patients harbored both a KRAS missense mutation and an amplification. In addition to KRAS, several other altered biomarkers were relatively prevalent, including TP53 (63.3%), CDKN2A (25.3%), ARID1A (9.1%), CDKN2B (7.0%), BRCA2 (4.4%), MEN1 (3.9%) and MTAP (3.6%). TP53 alterations were significantly overrepresented in KRAS-altered cancers. Alterations at MEN1, DAXX, ATRX, SETD2 and CREBBP, and high tumor mutational burden (TMB-high) were all overrepresented in cancers lacking KRAS alterations. In addition, all 19 (4.9%) actionable gene fusions involving oncogenic drivers (6 BRAF, 6 FGFR1/2, 3 NRG1, 2 RET, 1 RAF1, 1 ROS1) were found only in cancers lacking a KRAS alteration. Conclusions: Our study shows differences in the genomic profile based on KRAS status. We identified potentially targetable gene fusions and other alterations enriched in pancreatic tumors lacking KRAS alterations, suggesting several therapies may be reasonable options in such patients. Additionally, this analysis underscores the benefit of whole transcriptome profiling that identified actionable fusions in 4.9% of patient samples, all of which were unaltered at KRAS. Citation Format: Gargi D. Basu, Snehal G. Thakkar, David W. Hall, Cynthia A. Flannery, Satish Seerapu, Maen Abdelrahim. Genomic profiling of pancreatic cancer by KRAS status [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr A070.

Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines

Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis

Pancreatic Cancer Genomes Reveal Aberrations in Axon Guidance Pathway Genes

Biological Characteristics of Pancreatic Ductal Adenocarcinoma: Initiation to Malignancy, Intracellular to Extracellular.

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses.

Single-cell Transcriptome Reveals the Heterogeneity of Malignant Ductal Cells and the Prognostic Value of REG4 and SPINK1 in Primary Pancreatic Ductal Adenocarcinoma

Whole genomes redefine the mutational landscape of pancreatic cancer

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers

Abstract A070: Genomic profiling of pancreatic cancer by KRAS status

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer

Imaging , Diagnosis , Prognosis Integrative Survival-Based Molecular Pro fi ling of Human Pancreatic Cancer

Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma

Genetic polymorphisms and their influence on pancreatic adenocarcinoma progression

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

Genomic analyses identify molecular subtypes of pancreatic cancer

Mutation Profiling Of Cancer And Stromal Cells From Patients With Pancreatic Ductal Adenocarcinoma.

Elevated Expression of Cell Adhesion, Metabolic, and Mucus Secretion Gene Clusters Associated with Tumorigenesis, Metastasis, and Poor Survival in Pancreatic Ductal Adenocarcinoma

Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer

Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy

Identification of Genomic Alterations and Associated Transcriptomic Profiling Reveal the Prognostic Significance of MMP14 and PKM2 in Patients with Pancreatic Cancer.

Discovery and Analysis of Pancreatic Adenocarcinoma Genes Using Cdna Microarrays